AFQ056 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dyskinesias

Conditions

Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders, Anti-Dyskinesia Agents

Trial Timeline

Apr 1, 2012 → Apr 1, 2013

NCT ID

NCT01491529

About AFQ056 + Placebo

AFQ056 + Placebo is a phase 2 stage product being developed by Novartis for Dyskinesias. The current trial status is completed. This product is registered under clinical trial identifier NCT01491529. Target conditions include Dyskinesias, Parkinson Disease, Movement Disorders.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04771143	Phase 1	Withdrawn	Jul 21, 2021	Jan 3, 2022	Cocaine Use Disorder
NCT03242928	Phase 2	Completed	Dec 4, 2017	Dec 16, 2019	Cocaine-related Disorder
NCT02920892	Phase 2	Completed	Aug 17, 2017	May 17, 2022	Fragile X Syndrome
NCT01813019	Phase 2	Terminated	Nov 1, 2013	Nov 1, 2014	Patient Diagnosed With OCD and Resistant to SSRI Treatment
NCT01491529	Phase 2	Completed	Apr 1, 2012	Apr 1, 2013	Dyskinesias
NCT01385592	Phase 2	Completed	Nov 1, 2011	Sep 1, 2012	Dyskinesias
NCT01357239	Phase 2	Completed	May 1, 2011	Jan 1, 2014	Fragile X Syndrome
NCT01253629	Phase 2	Completed	Nov 1, 2010	Aug 1, 2013	Fragile X Syndrome
NCT01019473	Phase 2	Terminated	Nov 1, 2009	—	Huntington's Disease
NCT00888004	Phase 2	Completed	Mar 1, 2009	—	Parkinson's Disease
NCT00582673	Phase 2	Completed	Oct 1, 2007	—	Parkinson's Disease

Competing Products

4 competing products in Dyskinesias

See all competitors

Product	Company	Stage	Hype Score
Levodopa-carbidopa intestinal gel	AbbVie	Phase 3	77
AFQ056	Novartis	Phase 2	52
AQW051 + AQW051 + Placebo	Novartis	Phase 2	52
AFQ056 + Placebo	Novartis	Phase 2	52

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved